Osborne Clarke advises King's College London on formation of Cytolytix Limited with ValiRx PLC to develop triple negative breast cancer treatment

International law practice Osborne Clarke has advised King's College London on its establishment with ValiRx PLC ("ValiRx") of Cytolytix Limited ("Cytolytix), a new ValiRx subsidiary formed to progress the preclinical development of its triple negative breast cancer treatment, CLX001 based on IP licensed from King's College London.

Osborne Clarke's team was led by Partner Justin Starling and included Senior Associate Magnus Williams.

The development of CLX001, a peptide designed to destroy cancer cells without requiring specific cell markers or gene mutations for activity, will be led by Essex-based life science company, ValiRx as the major shareholder in Cytolytix. Oversight will be provided by the board Cytolytix board, including Kings College London and the academic inventors of CLX001, Martin Ulmschneider and Charles Chen.

Triple negative breast cancer accounts for around 15% of breast cancers. It is often more aggressive, harder to treat and more likely to recur than other cancers. The CLX001 treatment will have the potential for expansion into ovarian cancer and other solid tumour cancers.

Osborne Clarke's Corporate team works with clients across the life sciences and healthcare sector. The team advises at every stage of company development across all corporate issues, from equity and debt fundraisings to M&A, IPOs and JVs.

Share
Corporate communications and press contacts

If you are a journalist and would like comment or background from our legal experts, we can help. Our team will put you in touch with the best person. View a full list of our international press contacts by jurisdiction here.

Connect with one of our experts